Clinical trials: Depressive Episodes
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Severe Mental Disorder, Schizophrenia
Development of a Model for Digital Monitoring of the Mental State of the Hospitalized Patient
This study presents the development and validation of a unique Digital Experience Sampling Method (ESM) questionnaire specifically adapted for monitoring changes in the mental state of patients during psychiatric hospitalization.
- Conditions
- Severe Mental Disorder, Schizophrenia, Personality Disorders, Mood Disorders
- Trial name
- NCT06182787
- Where
- Israel
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Major Depressive Episode
Depressive Symptoms and Subjective Stress in the Course of the Menstrual Cycle - an Ambulatory Assessment Study.
Background: Major changes in female sex hormone concentrations influence the development of depressive symptoms in women. This hypothesis has been thoroughly investigated with regard to the menopause, the postpartal phase and…
- Trial name
- DepCy (NCT04086316)
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Freie Universität Berlin
Major Depression, Depressive Episodes
Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health
The purpose of this randomized multiple-site clinical study is to determine whether a revised CATCH-IT (Internet-based depression prevention program) is more effective than a general health education Internet intervention (Health…
- Trial name
- CATCH-IT (NCT01893749)
- Testing
- CATCH-IT
- Where
- 7 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Benjamin Van Voorhees, MD, MPH
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depressive Episodes, Bipolar I Depression
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
A clinical trial to study the efficacy and safety of an investigational drug in people with major depressive episodes associated with with Bipolar I disorder (bipolar I depression) Participants in the study will either receive…
- Trial name
- NCT05169710
- Testing
- SEP-4199 CR 200 mg, SEP-4199 CR 400 mg
- Where
- 89 sites in United States, Bulgaria and 4 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Episode
Medibio DDA Confirmatory Performance Study
This study will determine whether the Medibio Depression Diagnostic Aid exceeds minimally acceptable thresholds for sensitivity and sensitivity in cases with a current depression episode and non-depressed controls.
- Trial name
- NCT03529513
- Testing
- Medibio Depression Diagnostic Aid, Mini International Neuropsychiatric Interview, Hamilton Rating Scale for Depression - 17 Item
- Where
- 8 sites in United States, Australia
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Medibio Limited
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Depressive Disorder, Major
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in…
- Trial name
- COMPASS (NCT00629551)
- Testing
- saredutant (SR48968), paroxetine
- Where
- 8 sites in United States, Chile and 6 more
- Volunteers
- 825 people
- Sponsor
- Sanofi
Depression
A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.
- Trial name
- TRY FIRST (NCT00666757)
- Testing
- duloxetine, fluoxetine, citalopram
- Where
- 61 sites in United States
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Treatment Resistant Depression, Major Depressive Episode
University of Iowa Interventional Psychiatry Service Patient Registry
The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD).
- Conditions
- Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder
- Trial name
- NCT04480918
- Testing
- Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Mark Niciu
Major Depressive Disorder, Major Depressive Disorder, Recurrent
Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway
Major depressive disorder(MDD) is a complex and heterogeneous mental disorder. Repeated transcranial magnetic stimulation (rTMS), as a non-invasive neuroregulatory technique, has shown a promising function in the treatment of…
- Trial name
- NCT05913960
- Testing
- accelerated intermittent theta burst stimulation, high frequency stimulation
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Major Depressive Episode
Pain Perception in Suicidal Behavior Vulnerability
In France, almost 1 death on 50 is a suicide. The suicide occurs in unbearable psychic pain where mental trouble has a major influence. It is classified as preventable mortality.
- Trial name
- DOCS (NCT02915679)
- Testing
- Blood sample for genetic purpose, psychiatric assessment and pain investigation
- Where
- France
- Volunteers
- 167 people
- Sponsor
- University Hospital, Montpellier
Bipolar Disorder
Lamotrigine Phase III Study in Bipolar I Disorder
This registration study in China is a multi-centre, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of lamotrigine in the prevention of recurrence/relapse of mood episodes in subjects with…
- Trial name
- NCT01602510
- Testing
- Lamotrigine
- Where
- 21 sites in China
- Volunteers
- 265 people
- Sponsor
- GlaxoSmithKline
Major Depressive Episode
Cohort of Patients Suffering From Major Depressive Episode With Evaluation of Sleep, Circadian Rhythms and Psychiatric Disorders
Despite international efforts to identify biomarkers of depression, none has been transferred to clinical practice, neither for diagnosis, evolution, nor therapeutic response.
- Trial name
- SoPsy-SoSad (NCT05866991)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Depression, Depressive Disorder, Treatment-Resistant
OSU6162 as add-on in SSRI/SNRI-resistant Depression
This is a randomised, placebo-controlled, parallel-group trial comparing OSU6162 at flexible dosage with placebo as add-on to treatment with an SSRI/SNRI in patients with depression that have not responded to treatment with an…
- Conditions
- Depression, Depressive Disorder, Treatment-Resistant, Depressive Disorder, Depressive Episode
- Trial name
- ODEN (NCT05641623)
- Testing
- OSU6162
- Where
- 4 sites in Sweden
- Volunteers
- 180 people
- Sponsor
- Göteborg University
Bipolar I Disorder
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder
In this study, quetiapine is being tested for the possible treatment of bipolar I disorder with an acute depressive episode in children and adolescents.
- Trial name
- NCT00232414
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Depressive Episode, Electroconvulsive Therapy
RCT for Electroconvulsive Treatment Followed by Cognitive Control Training
Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high.
- Conditions
- Depressive Episode, Electroconvulsive Therapy, Cognitive Remediation
- Trial name
- ECT-CCT (NCT05683028)
- Testing
- Cognitive Control Training, Active Control
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- University Hospital, Ghent